Skip to main content

Table 1 Patients demographic and clinical characteristics

From: High-dose versus low-dose ergocalciferol for correcting hypovitaminosis D after fragility hip fracture: a randomized controlled trial

Clinical variables Low-dose group (n = 70) High-dose group (n = 70) p-value
Female gender, n (%) 52 (74.3) 49 (70.0) 0.575
Age (years), mean ± SD 78.5 ± 9.3 80.1 ± 10.0 0.311
Body mass index (kg/m2), mean ± SD 22.7 ± 3.6 22.5 ± 4.2 0.731
Charlson comorbidity index (CCI)
 - 0–1 46 (65.7) 47 (67.1) 0.840
 - 2–3 23 (32.9) 21 (30.0)  
 - >  3 1 (1.4) 2 (2.9)  
Type of hip fracture, n (%)
 - Intertrochanteric fracture 34 (48.6) 38 (54.3) 0.112
 - Femoral neck fracture 36 (51.4) 32 (45.7)  
Treatment, n (%)
 - Conservative 1 (1.4) 2 (2.9) 0.691
 - Multiple screw fixation 3 (4.3) 2 (2.9)  
 - Dynamic hip screw fixation 8 (11.4) 4 (5.7)  
 - Intramedullary nailing 30 (42.9) 33 (47.1)  
 - Arthroplasty 28 (40.0) 29 (41.4)  
Previous functional status, n (%)
 - Outdoor 48 (68.6) 40 (57.1) 0.235
 - Indoor 22 (31.4) 30 (42.9)  
Pre-operative ambulatory status, n (%)
 - Independent without gait aid 43 (61.4) 39 (55.7) 0.372
 - Single cane 16 (22.9) 14 (20.0)  
 - Tripod cane 3 (4.3) 6 (8.6)  
 - Quad cane 0 (0) 0 (0)  
 - Pick up walker 7 (10.0) 8 (11.4)  
 - Wheel chair 0 (0.0) 2 (2.9)  
 - Bed bound 1 (1.4) 1 (1.4)